Mesothelioma

Shares were down 10% seeing positive Onconase results.

BellwetherReport.com is a leading online research firm for international investors looking to get an edge over their portfolio.

Investors seeking the most up to date information on Alfacell Corporation are invited to sign up for a free complimentary subscription to www.bellwetherreport.com.

No credit card needed!

Biotechnology company Alfacell Corp.

said Monday preclinical studies of its developing drug Onconase showed it has potential in fighting tumors in non-small cell lung cancer and breast cancer.

The drug is already in late-stage clinical development for malignant Shares of Alfacell jumped 41 cents, or 16.9 percent, to $2.91 on the Nasdaq Stock Market in afternoon trading.

The stock has traded between 73 cents and $3.94 over the last 52 weeks.

More information on Alfacell Corporation available in the members section of www.BellwetherReport.com.

To review research on Alfacell Corporation as well as many more exciting articles we encourage you to visit www.bellwetherreport.com.

You can find these reports under the "Today's Articles" section.

No credit Card Needed!

!

The Bellwether Report will continue to resea...

Read more...